Cannabis Science (OTCMKTS: CBIS) and BioTelemetry (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.
Insider & Institutional Ownership
82.4% of BioTelemetry shares are owned by institutional investors. 9.6% of BioTelemetry shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Cannabis Science and BioTelemetry, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioTelemetry has a consensus price target of $43.50, suggesting a potential upside of 56.47%. Given BioTelemetry’s higher probable upside, analysts clearly believe BioTelemetry is more favorable than Cannabis Science.
Risk and Volatility
Cannabis Science has a beta of -3.62, suggesting that its share price is 462% less volatile than the S&P 500. Comparatively, BioTelemetry has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.
Earnings and Valuation
This table compares Cannabis Science and BioTelemetry’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioTelemetry||$208.33 million||4.32||$53.43 million||$1.29||21.55|
BioTelemetry has higher revenue and earnings than Cannabis Science.
This table compares Cannabis Science and BioTelemetry’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
BioTelemetry beats Cannabis Science on 9 of the 9 factors compared between the two stocks.
About Cannabis Science
Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.
BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company’s research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).
Receive News & Ratings for Cannabis Science Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannabis Science Inc. and related companies with MarketBeat.com's FREE daily email newsletter.